Toshihiko Matsumoto

Dr. Toshihiko Matsumoto

Kobe City Medical Center General Hospital
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2017 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
HYHideomi Yamashita
Hideomi Yamashita
KJKeiichi Jingu
Keiichi Jingu
YNYuzuru Niibe
Yuzuru Niibe
KKKuniaki Katsui
Kuniaki Katsui
TMToshihiko Matsumoto
Toshihiko Matsumoto
ATAtsuro Terahara
Atsuro Terahara
This study evaluated the treatment results of lymph node (LN) oligo-recurrence in esophageal cancer patients treated with salvage radiotherapy (RT) in a multi-institutional retrospective study. Eligibility criteria for this retrospective analysis were: the primary lesion of esophageal cancer was controlled; from one to five LN recurrences; total RT dose ≥45 Gy to exclude palliative RT; without recurrence other than LN; and salvage RT for LN recurrence was given between January 2000 and April 2015. The median follow-up time for the 93 living patients was 29.6 months. Two hundred thirty-seven patients were matched in five hospitals. The 3-year overall survival (OS) was 37%, local control was 45%, progression-free survival was 24%, and esophageal cancer-specific survival was 42%. On univariate analysis for OS, combined chemotherapy (p = 0.000055), disease-free interval (DFI) ≥12 months (p = 0.0013), LN max diameter ≤22 mm (p = 0.0052), and Karnofsky performance status ≥80% (p = 0.030) were associated with a significantly better prognosis. On multivariate analysis, significant differences were seen for combined chemotherapy (p = 0.000018), DFI (p = 0.0027), and LN max diameter (p = 0.018). LN oligo-recurrence following treatment for esophageal cancer was not a terminal-stage event. Moreover, cure may be possible by chemoradiation therapy with a long DFI (≥12 months) and small size (≤22 mm).

4 August 2022 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
TITatsuki Ikoma
Tatsuki Ikoma
MSMototsugu Shimokawa
Mototsugu Shimokawa
TMToshihiko Matsumoto
Toshihiko Matsumoto
BSBoku Shogen
Boku Shogen
TYTomoyo Yasuda
Tomoyo Yasuda
HSHironaga Satake
Hironaga Satake

1 April 2020 in Pancreas
Verified
Journal Article
Closed access
TMToshihiko Matsumoto
Toshihiko Matsumoto
YKYusuke Kurioka
Yusuke Kurioka
UOUkyo Okazaki
Ukyo Okazaki
YMYu Matsuo
Yu Matsuo
SKShogo Kimura
Shogo Kimura
HMHirofumi Morishita
Hirofumi Morishita
Objectives: There is no standard chemotherapy for advanced pancreatic cancer (APC) after gemcitabine plus nab-paclitaxel (GP) failure. The aim of this study was to evaluate the efficacy and safety of FOLFIRINOX (5-Fluorouracil, leucovorin, irinotecan, and oxaliplatin) (5-Fluorouracil, leucovorin, irinotecan, and oxaliplatin) (FFX) and modified FFX (mFFX) for APC patients after GP failure. Methods: We retrospectively evaluated the efficacy and safety of FFX in APC patients who were refractory or intolerant of GP. Results: Between July 2014 and October 2018, 23 patients received FFX after failure of GP. The overall response rate (RR) was 23%, and the disease control rate (DCR) was 68%. The median progression-free survival (PFS) was 5.3 months (95% confidence interval, 2.5–8.9), and the median overall survival (OS) was 12.1 months (95% confidence interval, 4.0–14.2). Twelve patients received FFX, and 11 patients received mFFX. In the FFX group, the RR was 9%, the DCR was 73%, the PFS was 5.3 months, and the OS was 6.9 months. In the mFFX group, the RR was 23%, the DCR was 64%, the PFS was 4.3 months, and the OS was 12.8 months. There was no significant difference between the groups. Conclusions: FOLFIRINOX has potential activity for patients with APC in whom GP failed.

17 April 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TMToshihiko Matsumoto
Toshihiko Matsumoto
SYShogo Yamamura
Shogo Yamamura
TITatsuki Ikoma
Tatsuki Ikoma
YKYusuke Kurioka
Yusuke Kurioka
KDKeitaro Doi
Keitaro Doi
HSHironaga Satake
Hironaga Satake
Trastuzumab deruxtecan (T-DXd) has shown promising efficacy against HER2-positive advanced gastric cancer (AGC). However, data on its real-world efficacy in AGC patients are insufficient, and the predictive marker of T-DXd is unclear. In this multi-center retrospective study, we collected clinical information of 18 patients with HER2-positive AGC who received T-DXd after intolerant or refractory responses to at least two prior regimens and analyzed predictive factors. The median age was 71 years (range: 51–85), 13 men were included, and ECOG performance status (PS): 0/1/2/3 was 9/6/2/1. A total of 11 patients (61%) received prior immune checkpoint inhibitors (ICIs), 14 patients were HER2 3+, and 4 patients were HER2 2+/FISH positive. The median trastuzumab (Tmab)-free interval was 7.7 months (range: 2.8–28.6). The overall response rate was 41%, and the disease control rate was 76%. Median progression-free survival (PFS) was 3.9 months (95% CI: 2.6–6.5), and median overall survival (OS) was 6.1 months (95% CI: 3.7–9.4). PFS (6.5 vs. 2.9 months, p = 0.0292) and OS (9.2 vs. 3.7 months, p = 0.0819) were longer in patients who received prior ICIs than in those who had not. PFS (6.5 vs. 3.4 months, p = 0.0249) and OS (9.4 vs. 5.7 months, p = 0.0426) were longer in patients with an 8 month or longer Tmab-free interval. In patients with ascites, PFS (6.5 vs. 2.75 months, p = 0.0139) and OS (9.4 vs. 3.9 months, p = 0.0460) were shorter. T-DXd showed promising efficacy in HER2-positive AGC patients in a real-world setting. Pre-administration of ICIs and a sufficient Tmab-free interval may be predictive factors of T-DXd efficacy.

10 February 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TMToshihiko Matsumoto
Toshihiko Matsumoto
TITatsuki Ikoma
Tatsuki Ikoma
SYShogo Yamamura
Shogo Yamamura
KMKou Miura
Kou Miura
TTTakao Tsuduki
Takao Tsuduki
HYHisateru Yasui
Hisateru Yasui
Regorafenib is a standard salvage line therapy used for advanced colorectal cancer (CRC). Recently, trifluridine/tipiracil (TFTD) plus bevacizumab also showed promising efficacy as a salvage line therapy for advanced CRC. However, the efficacy and safety of regorafenib for patients with advanced CRC who have previously received TFTD plus bevacizumab is unclear. We retrospectively collected clinicopathologic data from patients with advanced CRC who received regorafenib after TFTD plus bevacizumab in multiple institutions between April 2017 and June 2020.Thirty-four advanced CRC patients who received regorafenib were analyzed. The median age was 66.5 (range 43–81 years), 11 patients were male, and all had an ECOG performance status(PS) of 0 or 1. Twenty-two patients had left-sided tumors, 18 patients had RAS mutants, and 1 patient had a BRAF V600E mutation. The response rate was 0%, and the disease control rate was 31%. The median progression-free survival was 70 days (95% CI: 56–91), and the overall survival was 233 days (95% CI: 188–324). Treatment was discontinued in 32 patients, and 28 (82%) discontinued treatment due to progressive disease. The major grade 3 and4 toxicities were proteinurea (29%), hypertension (26%), hand-foot syndrome(15%), and platelet decrease (6%). Regorafenib after TFTD plus bevacizumab showed efficacy similar to that of the previous study, and no new adverse events were observed.

22 July 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
TMToshihiko Matsumoto
Toshihiko Matsumoto
YYYosuke Yamamoto
Yosuke Yamamoto
YKYusuke Kuriona
Yusuke Kuriona
UOUkyo Okazaki
Ukyo Okazaki
SKShogo Kimura
Shogo Kimura
MTMasahiro Takatani
Masahiro Takatani
Background: Nivolumab has changed the treatment of advanced gastric cancer (AGC). Nivolumab shows better outcomes compared to best supportive care among AGC patients who received at least two prior regimens. However, there are no reliable data regarding AGC patients with poor performance status (PS) who received nivolumab. We investigated the efficacy and safety of nivolumab among AGC patients with poor PS. Methods: We retrospectively collected clinicopathologic data from patients with AGC who underwent nivolumab monotherapy at our institution from October 2017 to June 2019. Results: Forty-nine AGC patients who received nivolumab were assessed. Twenty-seven patients had PS 0 or 1 (Good group) and 22 had PS 2 or 3 (Poor group). The median progression-free survival and overall survival durations were 2.0 and 6.0 months in the Good group, respectively, and 1.2 and 2.8 months in the Poor group, respectively. The overall survival was significantly shorter in the Poor group (6.0 vs 2.8 months, p = 0.0255). The disease control rates were 23 and 9% in the Good and Poor groups, respectively. Thirty-three percent of patients experienced immune-related adverse events in the Good group, and 18% in the Poor group. Conclusion: Nivolumab is feasible but insufficient as third- or later-line treatment for AGC patients with poor PS.